1
|
Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stàhl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, Liu Y, Lopez-Gitlitz A, Francis P, Bevans KB, Fizazi K. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. J Manag Care Spec Pharm 2023; 29:758-768. [PMID: 37404070 PMCID: PMC10387937 DOI: 10.18553/jmcp.2023.29.7.758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2023]
Abstract
BACKGROUND: Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal cancer. The phase 2 GALAHAD trial (NCT02854436) demonstrated that niraparib monotherapy is tolerable and efficacious in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations, particularly those with breast cancer gene (BRCA) alterations who had progressed on prior androgen signaling inhibitor therapy and taxane-based chemotherapy. OBJECTIVE: To report the prespecified patient-reported outcomes analysis from GALAHAD. METHODS: Eligible patients with alterations to BRCA1 and/or BRCA2 (BRCA cohort) and with pathogenic alterations in other HRR genes (other HRR cohort) were enrolled and received niraparib 300 mg once daily. Patient-reported outcome instruments included the Functional Assessment of Cancer Therapy-Prostate and the Brief Pain Inventory-Short Form. Changes from baseline were compared using a mixed-effect model for repeated measures. RESULTS: On average, health-related quality of life (HRQoL) improved in the BRCA cohort by cycle 3 (mean change = 6.03; 95% CI = 2.76-9.29) and was maintained above baseline until cycle 10 (mean change = 2.84; 95% CI = -1.95 to 7.63), whereas the other HRR cohort showed no early change in HRQoL from baseline (mean change = -0.07; 95% CI = -4.69 to 4.55) and declined by cycle 10 (mean change = -5.10; 95% CI = -15.3 to 5.06). Median time to deterioration in pain intensity and pain interference could not be estimated in either cohort. CONCLUSIONS: Patients with advanced mCRPC and BRCA alterations treated with niraparib experienced more meaningful improvement in overall HRQoL, pain intensity, and pain interference compared with those with other HRR alterations. In this population of castrate, heavily pretreated patients with mCRPC and HRR alterations, stabilization, and improvement in HRQoL may be relevant to consider when making treatment decisions. DISCLOSURES: This work was supported by Janssen Research & Development, LLC (no grant number). Dr Smith has received grants and personal fees from Bayer, Amgen, Janssen, and Lilly; and has received personal fees from Astellas Pharma, Novartis, and Pfizer. Dr Sandhu has received grants from Amgen, Endocyte, and Genentech; has received grants and personal fees from AstraZeneca and Merck; and has received personal fees from Bristol Myers Squibb and Merck Serono. Dr George has received personal fees from the American Association for Cancer Research, Axess Oncology, Capio Biosciences, Constellation Pharma, EMD Serono, Flatiron, Ipsen, Merck Sharp & Dohme, Michael J. Hennessey Association, Millennium Medical Publishing, Modra Pharma, Myovant Sciences, Inc., NCI Genitourinary, Nektar Therapeutics, Physician Education Resource, Propella TX, RevHealth, LLC, and UroGPO; has received grants and personal fees from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, and Pfizer; has received personal fees and nonfinancial support from Bayer and UroToday; has received grants from Calithera and Novartis; and has received grants, personal fees, and nonfinancial support from Exelixis, Inc., Sanofi, and Janssen Pharma. Dr Chi has received grants from Janssen during the conduct of the study; has received grants and personal fees from AstraZeneca, Bayer, Astellas Pharma, Novartis, Pfizer, POINT Biopharma, Roche, and Sanofi; and has received personal fees from Daiichi Sankyo, Merck, and Bristol Myers Squibb. Dr Saad has received grants, personal fees, and nonfinancial support from Janssen during the conduct of the study; and has received grants, personal fees, and nonfinancial support from AstraZeneca, Astellas Pharma, Pfizer, Bayer, Myovant, Sanofi, and Novartis. Dr Thiery-Vuillemin has received grants, personal fees, and nonfinancial support from Pfizer; has received personal fees and nonfinancial support from AstraZeneca, Janssen, Ipsen, Roche/Genentech, Merck Sharp & Dohme, and Astellas Pharma; and has received personal fees from Sanofi, Novartis, and Bristol Myers Squibb. Dr Olmos has received grants, personal fees, and nonfinancial support from AstraZeneca, Bayer, Janssen, and Pfizer; has received personal fees from Clovis, Daiichi Sankyo, and Merck Sharp & Dohme; and has received nonfinancial support from Astellas Pharma, F. Hoffman-LaRoche, Genentech, and Ipsen. Dr Danila has received research support from the US Department of Defense, the American Society of Clinical Oncology, the Prostate Cancer Foundation, Stand Up to Cancer, Janssen Research & Development, Astellas Pharma, Medivation, Agensys, Genentech, and CreaTV. Dr Gafanov has received grants from Janssen during the conduct of the study. Dr Castro has received grants from Janssen during the conduct of the study; has received grants and personal fees from Janssen, Bayer, AstraZeneca, and Pfizer; and has received personal fees from Astellas Pharma, Merck Sharp & Dohme, Roche, and Clovis. Dr Moon has received research funding from SeaGen, HuyaBio, Janssen, BMS, Aveo, Xencor, and has received personal fees from Axess Oncology, MJH, EMD Serono, and Pfizer. Dr Joshua has received nonfinancial support from Janssen; consulted or served in an advisory role for Neoleukin, Janssen Oncology, Ipsen, AstraZeneca, Sanofi, Noxopharm, IQvia, Pfizer, Novartis, Bristol Myers Squibb, Merck Serono, and Eisai; and received research funding from Bristol Myers Squibb, Janssen Oncology, Merck Sharp & Dohme, Mayne Pharma, Roche/Genentech, Bayer, MacroGenics, Lilly, Pfizer, AstraZeneca, and Corvus Pharmaceuticals. Drs Mason, Liu, Bevans, Lopez-Gitlitz, and Francis and Mr Espina are employees of Janssen Research & Development. Dr Mason owns stocks with Janssen. Dr Fizazi has participated in advisory boards and talks for Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis/AAA, Pfizer, and Sanofi, with honoraria to his institution (Institut Gustave Roussy); has participated in advisory boards for, with personal honoraria from, Arvinas, CureVac, MacroGenics, and Orion. Study registration number: NCT02854436.
Collapse
Affiliation(s)
- Matthew R Smith
- Hematology-Oncology Division, Massachusetts General Hospital, Harvard Medical School, Boston
| | - Shahneen Sandhu
- Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Australia
| | - Daniel J George
- Medical Oncology, Duke University School of Medicine, Duke Cancer Institute, Durham, NC
| | - Kim Nguyen Chi
- Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, Canada
| | - Fred Saad
- Centre Hospitalier de L’université de Montréal, Université de Montréal, Montréal, Québec, Canada
| | - Antoine Thiery-Vuillemin
- Medical Oncology Department, Centre Hospitalier Régional Universitaire Besancon – Hôpital Jean Minjoz, Besancon, France
| | - Olaf Stàhl
- Department of Oncology, Skåne University Hospital, Lund, Sweden
| | - David Olmos
- Department of Medical Oncology, Spanish National Cancer Research Centre, Madrid, Spain
- Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Spain, now with Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain
| | - Daniel C Danila
- Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Rustem Gafanov
- Medical Oncology, Russian Scientific Center of Roentgenology and Radiology, Moscow
| | - Elena Castro
- Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Spain, now with Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain
- Medical Oncology Department, Hospital Virgen de la Victoria, Málaga, Spain
| | - Helen Moon
- Hematology-Oncology, Kaiser Permanente Southern California, Riverside
| | - Anthony M Joshua
- Medical Oncology Department, Kinghorn Cancer Centre, St. Vincent’s Hospital Sydney, Darlinghurst, Australia
| | - Gary E Mason
- Clinical Oncology, Janssen Research & Development, LLC, Spring House, PA
| | - Byron M Espina
- Clinical Oncology, Janssen Research & Development, LLC, Los Angeles, CA
| | - Yan Liu
- Janssen Global Commercial Strategy Organization, Horsham, PA, now with Genmab US, Plainsboro, NJ
| | | | | | - Katherine B Bevans
- Janssen Global Commercial Strategy Organization, Horsham, PA, now with Genmab US, Plainsboro, NJ
| | - Karim Fizazi
- Medical Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
2
|
Grivas P, Barata PC, Moon H, Hutson TE, Gupta S, Sternberg CN, Dave V, Downey C, Shillington AC, Devgan G, Kirker M, Thakkar S, Katzenstein HM, Bhanegaonkar A, Liu F, Brown J, Sonpavde GP. Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II). J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
Abstract
465 Background: The JAVELIN Bladder 100 clinical trial demonstrated a significant overall survival and progression-free survival benefit with avelumab 1LM + best supportive care (BSC) vs BSC alone for la/mUC not progressing on platinum-based chemotherapy (PBC). PATRIOT-II aims to describe RW data for avelumab 1LM treatment (tx) of patients (pts) with la/mUC. Methods: PATRIOT-II collected data from pts with la/mUC treated in 37 geographically dispersed oncology practices/communities and academic centers in the US. Pts who initiated avelumab 1LM following PBC were retrospectively enrolled and will be followed up via medical record review for 52 weeks post avelumab 1LM initiation. This analysis focused on pt characteristics and tx data from la/mUC diagnosis through the PBC period and at avelumab 1LM initiation. Disease and PBC tx characteristics, as well as response to PBC, were assessed. All analyses were descriptive. Results: A total of 160 pts were enrolled (Table), 118 (74%) were white, non-Hispanic, 16 (10%), were Black, Asian, or Hispanic, and the rest unknown; 102 (64%) were current or former smokers. 77 (48%) were tested for PD-L1 via various assays, with 44 (57%) of those tumor samples reported as positive. 1L PBC was cisplatin-based in 100 (63%) of pts and carboplatin-based in 60 (38%). Pts received a median of 4 PBC cycles (interquartile range [IQR], 3-6) for a median of 13 weeks (IQR, 10-17). 31 (19%) discontinued PBC due to unacceptable side effects/toxicity. Best observed response was complete response in 21 (13%), partial response in 109 (68%), and stable disease in 17 (11%), with the remainder unknown. Median time to first imaging was 10 weeks (IQR, 5-14) after PBC initiation. 23 (14%) were hospitalized while receiving PBC, and 25 (16%) were seen in the emergency department. Pts proceeded to avelumab 1LM at a median of 4 weeks (IQR, 3-6) following PBC completion. Avelumab was administered at 800 mg every 2 weeks in 130 (81%), 10 mg/kg in 15 (9%), <800 mg in 8 (5%), and >800 mg in 7 (4%) pts. Conclusions: This ‘RW’ study offers valuable insights into characteristics and outcomes of pts with la/mUC treated in the US. Baseline factors, tx patterns and response to PBC were consistent with usual therapy paradigms in the 1L induction setting. Ongoing trials are evaluating the optimal number of PBC cycles and predictive biomarkers. Limitations include the retrospective nature, lack of randomization and central review, potential selection and confounding biases. [Table: see text]
Collapse
Affiliation(s)
- Petros Grivas
- University of Washington; Fred Hutchinson Cancer Center, Seattle, WA
| | | | | | | | - Shilpa Gupta
- Cleveland Clinic Taussig Cancer Center, Cleveland, OH
| | | | - Vaidehi Dave
- RTI Health Solutions, Research Triangle Park, NC
| | - Chad Downey
- RTI Health Solutions, Research Triangle Park, NC
| | | | | | | | | | | | | | | | - Jason Brown
- Division of Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
| | - Guru P. Sonpavde
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
3
|
O'Donnell PH, Rosenberg JE, Hoimes CJ, Petrylak DP, Milowsky MI, McKay RR, Srinivas S, Friedlander TW, Ramamurthy C, Bilen MA, Burgess EF, Mar N, Moon H, Geynisman DM, George S, Carret AS, Yu Y, Guseva M, Homet Moreno B, Flaig TW. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
Abstract
499 Background: In EV-103 Cohort K (NCT03288545), EV and P in combination (EV+P) showed encouraging antitumor activity and a manageable safety profile when used as 1L therapy in patients (pts) w/ la/mUC who are ineligible for cisplatin, a population w/ high unmet need. Here we report results of an analysis of prespecified Cohort K subgroups known to be associated w/ poor outcomes. Methods: Pts who are cisplatin-ineligible w/ previously untreated la/mUC were randomized 1:1 to EV (1.25 mg/kg) as monotherapy on Days 1 and 8 or in combination w/ P (200 mg) on Day 1 of 3-week cycles. Primary endpoint is cORR per RECIST v1.1 by blinded independent central review w/ no formal statistical comparison between arms. Secondary endpoints included duration of response and safety (e.g. treatment-related adverse events, TRAEs). The cORR analysis was performed in prespecified subgroups including age, ECOG PS, liver metastasis, PD-L1 expression status, metastatic disease site at baseline, and primary disease site of origin. Results: 149 pts were treated: EV+P n=76; EV n=73; cORRs across key subgroups for both EV+P and EV monotherapy are shown in the table. For EV+P overall cohort, cORR (95%CI): 64.5% (52.7, 75.1); median DOR was not reached. cORRs were consistent across subgroups for EV+P including those w/ ECOG PS score of 1-2: 62.8% (46.7, 77.0) and presence of liver metastasis: 53.8% (25.1, 80.8). Among TRAEs of special interest in the EV+P arm, skin reactions occurred in n=51 (67.1%); peripheral neuropathy occurred in n=46 (60.5%). For EV+P, 68.4% of pts had TRAEs leading to interruption of either EV or P; 48.7% of pts had TRAEs leading to EV dose reduction. Median duration of EV+P treatment was 11 cycles. Conclusions: EV+P showed promising cORR in 1L cisplatin-ineligible pts w/ la/mUC; activity was consistently observed across a range of pre-specified subgroups including those with poor prognosis. EV+P TRAEs were manageable w/ close monitoring and appropriate dose modifications w/ a meaningful duration of treatment. EV+P has the potential to address high unmet needs in 1L la/mUC and MIBC and is being further evaluated in 3 Phase 3 trials (NCT04223856, NCT04700124, NCT03924895). Clinical trial information: NCT03288545 . [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | - Matthew I. Milowsky
- University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| | - Rana R. McKay
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | - Sandy Srinivas
- Stanford University School of Medicine, Division of Oncology, Stanford, CA
| | | | - Chethan Ramamurthy
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | | | | | - Nataliya Mar
- University of California Irvine Medical Center, Orange, CA
| | | | | | - Saby George
- Roswell Park Comprehensive Cancer Center, Buffalo, NY
| | | | | | | | | | - Thomas W. Flaig
- University of Colorado Comprehensive Cancer Center, Aurora, CO
| |
Collapse
|
4
|
Abudinén F, Aggarwal L, Ahmed H, Ahn JK, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Babu V, Bae H, Bambade P, Banerjee S, Bansal S, Baudot J, Bauer M, Baur A, Beaubien A, Becker J, Bennett JV, Bernieri E, Bernlochner FU, Bertacchi V, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhardwaj V, Bianchi F, Bilka T, Biswas D, Bodrov D, Bolz A, Bonvicini G, Bozek A, Bračko M, Branchini P, Briere RA, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Chang MC, Chang P, Cheaib R, Cheema P, Chen C, Chen YQ, Chen YT, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Dattola F, De La Cruz-Burelo E, De La Motte SA, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dujany G, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finocchiaro G, Flood K, Fodor A, Forti F, Frey A, Fulsom BG, Gabrielli A, Ganiev E, Garcia-Hernandez M, Gaz A, Gellrich A, Ghevondyan G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Gradl W, Granderath S, Greenwald D, Gu T, Guan Y, Gudkova K, Guilliams J, Halder S, Hara K, Hartbrich O, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hohmann M, Humair T, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Iwasaki Y, Jackson P, Jacobs WW, Jaffe DE, Ji QP, Jin Y, Junkerkalefeld H, Kaleta M, Kandra J, Kang KH, Karl R, Karyan G, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kindo H, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar R, Kumara K, Kunigo T, Kwon YJ, Lacaprara S, Lam T, Lanceri L, Lange JS, Laurenza M, Leboucher R, Lee SC, Leitl P, Levit D, Li LK, Li SX, Li YB, Libby J, Liptak Z, Liu QY, Liventsev D, Longo S, Lueck T, Lyu C, Maggiora M, Maiti R, Maity S, Manfredi R, Manoni E, Marcello S, Marinas C, Martel L, Martini A, Massaccesi L, Masuda M, Matsuoka K, Matvienko D, McKenna JA, Meier F, Merola M, Milesi M, Miller C, Miyabayashi K, Mohanty GB, Molina-Gonzalez N, Moneta S, Moon H, Moser HG, Mrvar M, Mussa R, Nakamura I, Nakao M, Nakayama H, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nazaryan G, Niebuhr C, Nisar NK, Nishida S, Nishimura K, Ono H, Oskin P, Oxford ER, Pakhlova G, Paladino A, Panta A, Paoloni E, Pardi S, Parham K, Park H, Park SH, Passeri A, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Pham F, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raiz S, Reif M, Reiter S, Ripp-Baudot I, Rizzo G, Robertson SH, Roney JM, Rostomyan A, Rout N, Russo G, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schwanda C, Schwartz AJ, Seino Y, Selce A, Senyo K, Serrano J, Sfienti C, Shen CP, Shillington T, Shiu JG, Sibidanov A, Simon F, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stroili R, Strube J, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Takahashi M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Taniguchi N, Tenchini F, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Unger K, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Vobbilisetti V, Waheed E, Wakeling HM, Wang E, Wang MZ, Wang XL, Warburton A, Watanuki S, Welsch M, Wessel C, Wiechczynski J, Windel H, Won E, Xu XP, Yabsley BD, Yamada S, Yang SB, Ye H, Yelton J, Yin JH, Yoshihara K, Yusa Y, Zhang Y, Zhilich V, Zhou QD, Zhukova VI, Žlebčík R. Measurement of the Λ_{c}^{+} Lifetime. Phys Rev Lett 2023; 130:071802. [PMID: 36867815 DOI: 10.1103/physrevlett.130.071802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 07/25/2022] [Indexed: 06/18/2023]
Abstract
An absolute measurement of the Λ_{c}^{+} lifetime is reported using Λ_{c}^{+}→pK^{-}π^{+} decays in events reconstructed from data collected by the Belle II experiment at the SuperKEKB asymmetric-energy electron-positron collider. The total integrated luminosity of the data sample, which was collected at center-of-mass energies at or near the ϒ(4S) resonance, is 207.2 fb^{-1}. The result, τ(Λ_{c}^{+})=203.20±0.89±0.77 fs, where the first uncertainty is statistical and the second systematic, is the most precise measurement to date and is consistent with previous determinations.
Collapse
|
5
|
Abudinén F, Adachi I, Aggarwal L, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Babu V, Bahinipati S, Bambade P, Banerjee S, Bansal S, Baudot J, Baur A, Beaubien A, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bertholet E, Bessner M, Bhuyan B, Bianchi F, Bilka T, Biswas D, Bobrov A, Bodrov D, Bolz A, Bozek A, Bračko M, Branchini P, Browder TE, Budano A, Bussino S, Campajola M, Casarosa G, Cecchi C, Chekelian V, Chen C, Chen YQ, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cunliffe S, Dattola F, de Marino G, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Dhamija R, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dreyer S, Dubey S, Dujany G, Eliachevitch M, Epifanov D, Feichtinger P, Ferber T, Ferlewicz D, Fillinger T, Finck C, Finocchiaro G, Flood K, Fodor A, Forti F, Frey A, Fulsom BG, Ganiev E, Garcia-Hernandez M, Gaur V, Gaz A, Gellrich A, Giordano R, Giri A, Gobbo B, Godang R, Goldenzweig P, Gradl W, Granderath S, Graziani E, Greenwald D, Gu T, Gudkova K, Guilliams J, Hadjivasiliou C, Hara K, Hara T, Hayasaka K, Hayashii H, Hazra S, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hoek M, Hohmann M, Hsu CL, Iijima T, Inami K, Inguglia G, Ipsita N, Ishikawa A, Ito S, Itoh R, Iwasaki M, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Ji QP, Jia S, Jin Y, Junkerkalefeld H, Kakuno H, Kaliyar AB, Kandra J, Kang KH, Karl R, Karyan G, Kawasaki T, Ketter C, Kichimi H, Kiesling C, Kim CH, Kim DY, Kim KH, Kim YK, Kinoshita K, Kodyš P, Koga T, Kohani S, Kojima K, Konno T, Korobov A, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar R, Kumara K, Kunigo T, Kwon YJ, Lacaprara S, Lai YT, Lam T, Lange JS, Laurenza M, Leboucher R, Lee SC, Li LK, Li YB, Libby J, Lieret K, Liu QY, Liventsev D, Longo S, Lozar A, Lueck T, Lyu C, Maggiora M, Maiti R, Maity S, Manfredi R, Manoni E, Marcello S, Marinas C, Martel L, Martini A, Massaccesi L, Masuda M, Matsuoka K, McKenna JA, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mohanty GB, Molina-Gonzalez N, Moneta S, Moon H, Mrvar M, Nakamura I, Nakamura KR, Nakao M, Nakayama H, Narimani Charan A, Naruki M, Natkaniec Z, Natochii A, Nayak L, Nayak M, Nisar NK, Nishida S, Nishimura K, Ogawa S, Ono H, Oskin P, Pakhlova G, Paladino A, Panta A, Pardi S, Parham K, Park H, Park SH, Passeri A, Patra S, Paul S, Pedlar TK, Piccolo M, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat L, Praz C, Prell S, Prencipe E, Prim MT, Purwar H, Rad N, Rados P, Raiz S, Ramirez Morales A, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Robertson SH, Rodríguez Pérez D, Roney JM, Rostomyan A, Rout N, Sahoo D, Sanders DA, Sandilya S, Santelj L, Sato Y, Scavino B, Schueler J, Schwanda C, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shillington T, Shiu JG, Sibidanov A, Simon F, Singh JB, Skorupa J, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Sumihama M, Sumisawa K, Sutcliffe W, Suzuki SY, Svidras H, Tabata M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Tenchini F, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Ueda I, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Vobbilisetti V, Waheed E, Wakeling HM, Wang E, Wang MZ, Warburton A, Watanabe M, Watanuki S, Welsch M, Wessel C, Windel H, Won E, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yin JH, Yoshihara K, Yuan CZ, Yusa Y, Zani L, Zhang Y, Zhilich V, Zhou QD, Zhou XY, Zhukova VI, Žlebčík R. Search for a Dark Photon and an Invisible Dark Higgs Boson in μ^{+}μ^{-} and Missing Energy Final States with the Belle II Experiment. Phys Rev Lett 2023; 130:071804. [PMID: 36867830 DOI: 10.1103/physrevlett.130.071804] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Accepted: 11/29/2022] [Indexed: 06/18/2023]
Abstract
The dark photon A^{'} and the dark Higgs boson h^{'} are hypothetical particles predicted in many dark sector models. We search for the simultaneous production of A^{'} and h^{'} in the dark Higgsstrahlung process e^{+}e^{-}→A^{'}h^{'} with A^{'}→μ^{+}μ^{-} and h^{'} invisible in electron-positron collisions at a center-of-mass energy of 10.58 GeV in data collected by the Belle II experiment in 2019. With an integrated luminosity of 8.34 fb^{-1}, we observe no evidence for signal. We obtain exclusion limits at 90% Bayesian credibility in the range of 1.7-5.0 fb on the cross section and in the range of 1.7×10^{-8}-200×10^{-8} on the effective coupling ϵ^{2}×α_{D} for the A^{'} mass in the range of 4.0 GeV/c^{2}<M_{A^{'}}<9.7 GeV/c^{2} and for the h^{'} mass M_{h^{'}}<M_{A^{'}}, where ϵ is the mixing strength between the standard model and the dark photon and α_{D} is the coupling of the dark photon to the dark Higgs boson. Our limits are the first in this mass range.
Collapse
|
6
|
Rosenberg J, Milowsky M, Ramamurthy C, Mar N, McKay R, Friedlander T, Ferrario C, Bracarda S, George S, Moon H, Geynisman D, Petrylak D, Borchiellini D, Burgess E, Rey JM, Carret AS, Yu Y, Guseva M, Moreno BH, O'Donnell P. LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Kim H, Yoon S, Yun Y, Hur M, Moon H. M222 Evaluation of commutability of external quality assessment material for accuracy based survey of lipid tests. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
8
|
Kim H, Hur M, Kim S, Moon H, Yun Y. T248 Reference intervals for 10 platelet parameters on Mindray BC-6800 plus hematology analyzer. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Yoon S, Moon H, Yi A, Kim H, Chung H, Hur M, Yun Y, Yoo G. W071 Investigation of serial tests of quantiferon-tb gold in-tube and quantiferon-tb gold-plus in contacts to patients with active tuberculosis. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
10
|
Kim K, Jeong I, Moon H. M291 A survey on antinuclear antibodies testing in Korea. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Grivas P, Barata PC, Moon H, Hutson TE, Gupta S, Sternberg CN, Pickard AS, Dave V, Han N, Shillington AC, Devgan G, Kim R, Thakkar S, Katzenstein H, Bhanegaonkar A, Liu F, Sonpavde GP. PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.tps578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS578 Background: The randomized phase 3 JAVELIN Bladder 100 trial demonstrated overall and progression-free survival (OS and PFS) benefit with Ave 1LM for la/mUC not progressed with platinum-containing chemotherapy (PCT). PATRIOT II aims to understand real-world treatment (tx) patterns, patient-reported outcomes (PRO), and healthcare resource utilization (HCRU; eg, hospitalizations and emergency department visits) before and during Ave 1LM treatment. Methods: PATRIOT II is an ongoing, real-world, observational study in ≤25 US oncology centers with 1) an ambispective cohort of patients (pts) initiating PCT (n = 100), a subset of whom may continue to Ave 1LM and 2) a retrospective cohort initiated on Ave 1LM (n = 150). Sample size assumes noninferiority in HCRU and PRO pre and post 1LM initiation using paired t-tests with effect size of ≤0.3 as noninferior: ≥71 patients continuing to 1LM. In the ambispective cohort, pts with histologically confirmed la/mUC newly initiating 1L PCT are enrolled. While pts are receiving PCT and 1LM (for those who receive it), data will be collected on disease characteristics, response to tx, survival, adverse events (AEs), and HCRU for ≤52 wks after study initiation. PROs are captured using Rand SF-36 question 1, FACT Bladder Symptom Inventory – 18 and Cancer Treatment Satisfaction Questionnaire. Primary outcomes include OS and PFS from both PCT and 1LM initiation; secondary outcomes are changes in PROs and HCRU from PCT to 1LM. Analysis will be conducted at following time points: 1) baseline characteristics after full enrollment; 2) 6 months after study initiation to assess tx changes and rationale, OS, PFS, HCRU, and PRO changes from baseline; 3) at study conclusion (wk 52 after study initiation). In the retrospective cohort, pts with la/mUC who initiated Ave 1LM are enrolled. Chart data encompasses PCT and 1LM periods. Disease characteristics, response to tx, survival, AEs, and HCRU are collected. Primary outcomes are OS and PFS from initiation of PCT and 1LM start. Secondary outcomes are changes in HCRU before and after 1LM. Analysis will be conducted at following time points: 1) baseline characteristics after full enrollment, PCT, and response to tx; 2) 6 months after study initiation to assess tx changes since baseline, including dose changes, tx discontinuation/change rationale, survival rates (censoring for differential duration of follow-up), and HCRU outcomes; 3) at study conclusion to analyze endpoints up to wk 52 following study initiation. Analyses for both cohorts include Kaplan-Meier and Cox regression for time-to-event endpoints and paired t-tests for pre/post 1LM. Enrollment commenced in June 2021. 5 and 18 pts are enrolled to date in the ambispective and retrospective cohorts, respectively, from 6 of 11 activated sites. Initial results are anticipated in May 2022.
Collapse
Affiliation(s)
- Petros Grivas
- University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA
| | | | - Helen Moon
- Southern California Permanente Medical Group, Riverside, CA
| | | | - Shilpa Gupta
- Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
| | | | | | - Vaidehi Dave
- RTI Health Solutions, Research Triangle Park, NC
| | - Natalia Han
- RTI Health Solutions, Research Triangle Park, NC
| | | | | | | | | | | | | | | | - Guru P. Sonpavde
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
12
|
Abudinén F, Adachi I, Adamczyk K, Aggarwal L, Ahmed H, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev V, Babu V, Bacher S, Bae H, Baehr S, Bahinipati S, Bambade P, Banerjee S, Bansal S, Barrett M, Baudot J, Bauer M, Baur A, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bhardwaj V, Bianchi F, Bilka T, Bilokin S, Biswas D, Bobrov A, Bodrov D, Bolz A, Bozek A, Bračko M, Branchini P, Braun N, Briere RA, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Červenkov D, Chang MC, Chang P, Cheaib R, Chekelian V, Chen C, Chen YT, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Choudhury S, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Czank T, Dattola F, De La Cruz-Burelo E, de Marino G, De Nardo G, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dorigo M, Dort K, Dossett D, Dubey S, Duell S, Dujany G, Ecker P, Epifanov D, Ferber T, Ferlewicz D, Finocchiaro G, Flood K, Fodor A, Forti F, Fulsom BG, Gabrielli A, Gabyshev N, Gaz A, Gellrich A, Giakoustidis G, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Golob B, Gradl W, Graziani E, Greenwald D, Gu T, Guan Y, Gudkova K, Guilliams J, Hadjivasiliou C, Halder S, Hara K, Hara T, Hartbrich O, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hirata H, Hoek M, Hohmann M, Hsu CL, Humair T, Iijima T, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki M, Iwasaki Y, Jacobs WW, Jaffe DE, Jang EJ, Jia S, Jin Y, Junkerkalefeld H, Kakuno H, Kaliyar AB, Kandra J, Kang KH, Karl R, Karyan G, Kato Y, Kawasaki T, Kiesling C, Kim CH, Kim DY, Kim YK, Kim Y, Kimmel TD, Kinoshita K, Kodyš P, Koga T, Kohani S, Konno T, Korpar S, Kovalenko E, Kowalewski R, Kraetzschmar TMG, Krinner F, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar M, Kumar R, Kumara K, Kurz S, Kuzmin A, Kwon YJ, Lacaprara S, Lalwani K, Lam T, Lanceri L, Lange JS, Laurenza M, Lautenbach K, Le Diberder FR, Lee SC, Leitl P, Levit D, Li C, Li LK, Libby J, Lieret K, Liptak Z, Liu QY, Liventsev D, Longo S, Lueck T, Lyu C, Manfredi R, Manoni E, Marinas C, Martini A, Matsuda T, Matsuoka K, Matvienko D, McKenna JA, Meier F, Merola M, Metzner F, Miller C, Miyabayashi K, Mizuk R, Mohanty GB, Molina-Gonzalez N, Moon H, Moser HG, Mrvar M, Murphy C, Mussa R, Nakamura I, Nakamura KR, Nakao M, Nakazawa H, Natkaniec Z, Natochii A, Nazaryan G, Niebuhr C, Niiyama M, Nisar NK, Nishida S, Nishimura K, Ogawa S, Onishchuk Y, Ono H, Onuki Y, Oskin P, Oxford ER, Ozaki H, Pakhlov P, Paladino A, Pang T, Panta A, Paoloni E, Pardi S, Park H, Park SH, Paschen B, Passeri A, Pathak A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Pham F, Piccolo M, Piilonen LE, Pinna Angioni G, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat G, Popov V, Praz C, Prell S, Prencipe E, Prim MT, Purohit MV, Purwar H, Rad N, Rados P, Raiz S, Reiter S, Remnev M, Ripp-Baudot I, Rizzo G, Rizzuto LB, Robertson SH, Roney JM, Rostomyan A, Rout N, Rozanska M, Sahoo D, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schueler J, Schwanda C, Schwartz AJ, Seino Y, Selce A, Senyo K, Serrano J, Sfienti C, Shiu JG, Shwartz B, Sibidanov A, Simon F, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Strube J, Sumihama M, Sutcliffe W, Suzuki SY, Svidras H, Tabata M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Taniguchi N, Tenchini F, Tiwary R, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Tsuboyama T, Ueda I, Uehara S, Uematsu Y, Uglov T, Unger K, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Usov YV, Vahsen SE, van Tonder R, Varner GS, Vinokurova A, Vitale L, Vossen A, Waheed E, Wakeling HM, Wang E, Wang MZ, Wang XL, Warburton A, Watanabe M, Welsch M, Wessel C, Wiechczynski J, Won E, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yelton J, Yin JH, Yoshihara K, Yusa Y, Zani L, Zhilich V, Zhou QD, Zhou XY, Zhukova VI, Žlebčík R. Precise Measurement of the D^{0} and D^{+} Lifetimes at Belle II. Phys Rev Lett 2021; 127:211801. [PMID: 34860075 DOI: 10.1103/physrevlett.127.211801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Accepted: 10/20/2021] [Indexed: 06/13/2023]
Abstract
We report a measurement of the D^{0} and D^{+} lifetimes using D^{0}→K^{-}π^{+} and D^{+}→K^{-}π^{+}π^{+} decays reconstructed in e^{+}e^{-}→cc[over ¯] data recorded by the Belle II experiment at the SuperKEKB asymmetric-energy e^{+}e^{-} collider. The data, collected at center-of-mass energies at or near the ϒ(4S) resonance, correspond to an integrated luminosity of 72 fb^{-1}. The results, τ(D^{0})=410.5±1.1(stat)±0.8(syst) fs and τ(D^{+})=1030.4±4.7(stat)±3.1(syst) fs, are the most precise to date and are consistent with previous determinations.
Collapse
Affiliation(s)
- F Abudinén
- INFN Sezione di Trieste, I-34127 Trieste, Italy
| | - I Adachi
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - K Adamczyk
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342, Poland
| | - L Aggarwal
- Panjab University, Chandigarh 160014, India
| | - H Ahmed
- St. Francis Xavier University, Antigonish, Nova Scotia, B2G 2W5, Canada
| | - H Aihara
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - N Akopov
- Alikhanyan National Science Laboratory, Yerevan 0036, Armenia
| | - A Aloisio
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - N Anh Ky
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000, Vietnam
- Institute of Physics, Vietnam Academy of Science and Technology (VAST), Hanoi, Vietnam
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H Atmacan
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - V Aushev
- Taras Shevchenko National Univ. of Kiev, Kiev, Ukraine
| | - V Babu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - S Bacher
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342, Poland
| | - H Bae
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - S Baehr
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - S Bahinipati
- Indian Institute of Technology Bhubaneswar, Satya Nagar 751007, India
| | - P Bambade
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292, USA
| | - S Bansal
- Panjab University, Chandigarh 160014, India
| | - M Barrett
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - J Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg, France
| | - M Bauer
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - A Baur
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - J Becker
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - P K Behera
- Indian Institute of Technology Madras, Chennai 600036, India
| | - J V Bennett
- University of Mississippi, University, Mississippi 38677, USA
| | - E Bernieri
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
| | | | - M Bertemes
- Institute of High Energy Physics, Vienna 1050, Austria
| | - E Bertholet
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978, Israel
| | - M Bessner
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - V Bhardwaj
- Indian Institute of Science Education and Research Mohali, SAS Nagar, 140306, India
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - T Bilka
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic
| | - S Bilokin
- Ludwig Maximilians University, 80539 Munich, Germany
| | - D Biswas
- University of Louisville, Louisville, Kentucky 40292, USA
| | - A Bobrov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - D Bodrov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
- National Research University Higher School of Economics, Moscow 101000, Russian Federation
| | - A Bolz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - A Bozek
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342, Poland
| | - M Bračko
- J. Stefan Institute, 1000 Ljubljana, Slovenia
- Faculty of Chemistry and Chemical Engineering, University of Maribor, 2000 Maribor, Slovenia
| | - P Branchini
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
| | - N Braun
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - R A Briere
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T E Browder
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Budano
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
| | - S Bussino
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma, Italy
| | - M Campajola
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - L Cao
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - C Cecchi
- INFN Sezione di Perugia, I-06123 Perugia, Italy
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia, Italy
| | - D Červenkov
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic
| | - M-C Chang
- Department of Physics, Fu Jen Catholic University, Taipei 24205, Taiwan
| | - P Chang
- Department of Physics, National Taiwan University, Taipei 10617, Taiwan
| | - R Cheaib
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - V Chekelian
- Max-Planck-Institut für Physik, 80805 München, Germany
| | - C Chen
- Iowa State University, Ames, Iowa 50011, USA
| | - Y-T Chen
- Department of Physics, National Taiwan University, Taipei 10617, Taiwan
| | - B G Cheon
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763, South Korea
| | - K Chilikin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
| | | | - H-E Cho
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763, South Korea
| | - K Cho
- Korea Institute of Science and Technology Information, Daejeon 34141, South Korea
| | - S-J Cho
- Yonsei University, Seoul 03722, South Korea
| | - S-K Choi
- Gyeongsang National University, Jinju 52828, South Korea
| | - S Choudhury
- Indian Institute of Technology Hyderabad, Telangana 502285, India
| | - D Cinabro
- Wayne State University, Detroit, Michigan 48202, USA
| | - L Corona
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - L M Cremaldi
- University of Mississippi, University, Mississippi 38677, USA
| | - S Cunliffe
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - T Czank
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583, Japan
| | - F Dattola
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - E De La Cruz-Burelo
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360, Mexico
| | - G de Marino
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - G De Nardo
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - G De Pietro
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - M Destefanis
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - S Dey
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978, Israel
| | - A De Yta-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360, Mexico
| | - A Di Canto
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - F Di Capua
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | | | - Z Doležal
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic
| | | | - T V Dong
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000, Vietnam
| | - M Dorigo
- INFN Sezione di Trieste, I-34127 Trieste, Italy
| | - K Dort
- Justus-Liebig-Universität Gießen, 35392 Gießen, Germany
| | - D Dossett
- School of Physics, University of Melbourne, Victoria 3010, Australia
| | - S Dubey
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S Duell
- University of Bonn, 53115 Bonn, Germany
| | - G Dujany
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg, France
| | - P Ecker
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - D Epifanov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - T Ferber
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - D Ferlewicz
- School of Physics, University of Melbourne, Victoria 3010, Australia
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - K Flood
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Fodor
- McGill University, Montréal, Québec, H3A 2T8, Canada
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - B G Fulsom
- Pacific Northwest National Laboratory, Richland, Washington, D.C. 99352, USA
| | - A Gabrielli
- INFN Sezione di Trieste, I-34127 Trieste, Italy
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - N Gabyshev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - A Gaz
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova, Italy
| | - A Gellrich
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | | | - R Giordano
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - A Giri
- Indian Institute of Technology Hyderabad, Telangana 502285, India
| | - A Glazov
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - B Gobbo
- INFN Sezione di Trieste, I-34127 Trieste, Italy
| | - R Godang
- University of South Alabama, Mobile, Alabama 36688, USA
| | - P Goldenzweig
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - B Golob
- J. Stefan Institute, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - W Gradl
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, D-55099 Mainz, Germany
| | - E Graziani
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
| | - D Greenwald
- Department of Physics, Technische Universität München, 85748 Garching, Germany
| | - T Gu
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - Y Guan
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - K Gudkova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - J Guilliams
- University of Mississippi, University, Mississippi 38677, USA
| | - C Hadjivasiliou
- Pacific Northwest National Laboratory, Richland, Washington, D.C. 99352, USA
| | - S Halder
- Tata Institute of Fundamental Research, Mumbai 400005, India
| | - K Hara
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - T Hara
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - O Hartbrich
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K Hayasaka
- Niigata University, Niigata 950-2181, Japan
| | - H Hayashii
- Nara Women's University, Nara 630-8506, Japan
| | - S Hazra
- Tata Institute of Fundamental Research, Mumbai 400005, India
| | - C Hearty
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2, Canada
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1, Canada
| | - I Heredia de la Cruz
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360, Mexico
- Consejo Nacional de Ciencia y Tecnología, Mexico City 03940, Mexico
| | | | - A Hershenhorn
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1, Canada
| | - T Higuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583, Japan
| | - E C Hill
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1, Canada
| | - H Hirata
- Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
| | - M Hoek
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, D-55099 Mainz, Germany
| | - M Hohmann
- School of Physics, University of Melbourne, Victoria 3010, Australia
| | - C-L Hsu
- School of Physics, University of Sydney, New South Wales 2006, Australia
| | - T Humair
- Max-Planck-Institut für Physik, 80805 München, Germany
| | - T Iijima
- Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602, Japan
| | - K Inami
- Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
| | - G Inguglia
- Institute of High Energy Physics, Vienna 1050, Austria
| | - A Ishikawa
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - R Itoh
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - M Iwasaki
- Osaka City University, Osaka 558-8585, Japan
| | - Y Iwasaki
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408, USA
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E-J Jang
- Gyeongsang National University, Jinju 52828, South Korea
| | - S Jia
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443, China
| | - Y Jin
- INFN Sezione di Trieste, I-34127 Trieste, Italy
| | | | - H Kakuno
- Tokyo Metropolitan University, Tokyo 192-0397, Japan
| | - A B Kaliyar
- Tata Institute of Fundamental Research, Mumbai 400005, India
| | - J Kandra
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic
| | - K H Kang
- Kyungpook National University, Daegu 41566, South Korea
| | - R Karl
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - G Karyan
- Alikhanyan National Science Laboratory, Yerevan 0036, Armenia
| | - Y Kato
- Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602, Japan
| | - T Kawasaki
- Kitasato University, Sagamihara 252-0373, Japan
| | - C Kiesling
- Max-Planck-Institut für Physik, 80805 München, Germany
| | - C-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763, South Korea
| | - D Y Kim
- Soongsil University, Seoul 06978, South Korea
| | - Y-K Kim
- Yonsei University, Seoul 03722, South Korea
| | - Y Kim
- Korea University, Seoul 02841, South Korea
| | - T D Kimmel
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - K Kinoshita
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - P Kodyš
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic
| | - T Koga
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - S Kohani
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - T Konno
- Kitasato University, Sagamihara 252-0373, Japan
| | - S Korpar
- J. Stefan Institute, 1000 Ljubljana, Slovenia
- Faculty of Chemistry and Chemical Engineering, University of Maribor, 2000 Maribor, Slovenia
| | - E Kovalenko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - R Kowalewski
- University of Victoria, Victoria, British Columbia, V8W 3P6, Canada
| | | | - F Krinner
- Max-Planck-Institut für Physik, 80805 München, Germany
| | - P Križan
- J. Stefan Institute, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - P Krokovny
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - T Kuhr
- Ludwig Maximilians University, 80539 Munich, Germany
| | - J Kumar
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M Kumar
- Malaviya National Institute of Technology Jaipur, Jaipur 302017, India
| | - R Kumar
- Punjab Agricultural University, Ludhiana 141004, India
| | - K Kumara
- Wayne State University, Detroit, Michigan 48202, USA
| | - S Kurz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - A Kuzmin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - Y-J Kwon
- Yonsei University, Seoul 03722, South Korea
| | - S Lacaprara
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - K Lalwani
- Malaviya National Institute of Technology Jaipur, Jaipur 302017, India
| | - T Lam
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - L Lanceri
- INFN Sezione di Trieste, I-34127 Trieste, Italy
| | - J S Lange
- Justus-Liebig-Universität Gießen, 35392 Gießen, Germany
| | - M Laurenza
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma, Italy
| | - K Lautenbach
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille, France
| | - F R Le Diberder
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - S C Lee
- Kyungpook National University, Daegu 41566, South Korea
| | - P Leitl
- Max-Planck-Institut für Physik, 80805 München, Germany
| | - D Levit
- Department of Physics, Technische Universität München, 85748 Garching, Germany
| | - C Li
- Liaoning Normal University, Dalian 116029, China
| | - L K Li
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036, India
| | - K Lieret
- Ludwig Maximilians University, 80539 Munich, Germany
| | - Z Liptak
- Hiroshima University, Higashi-Hiroshima, Hiroshima 739-8530, Japan
| | - Q Y Liu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - D Liventsev
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
- Wayne State University, Detroit, Michigan 48202, USA
| | - S Longo
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - T Lueck
- Ludwig Maximilians University, 80539 Munich, Germany
| | - C Lyu
- University of Bonn, 53115 Bonn, Germany
| | - R Manfredi
- INFN Sezione di Trieste, I-34127 Trieste, Italy
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - C Marinas
- Instituto de Fisica Corpuscular, Paterna 46980, Spain
| | - A Martini
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - T Matsuda
- University of Miyazaki, Miyazaki 889-2192, Japan
| | - K Matsuoka
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - D Matvienko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - J A McKenna
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1, Canada
| | - F Meier
- Duke University, Durham, North Carolina 27708, USA
| | - M Merola
- INFN Sezione di Napoli, I-80126 Napoli, Italy
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli, Italy
| | - F Metzner
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - C Miller
- University of Victoria, Victoria, British Columbia, V8W 3P6, Canada
| | | | - R Mizuk
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
- National Research University Higher School of Economics, Moscow 101000, Russian Federation
| | - G B Mohanty
- Tata Institute of Fundamental Research, Mumbai 400005, India
| | - N Molina-Gonzalez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360, Mexico
| | - H Moon
- Korea University, Seoul 02841, South Korea
| | - H-G Moser
- Max-Planck-Institut für Physik, 80805 München, Germany
| | - M Mrvar
- Institute of High Energy Physics, Vienna 1050, Austria
| | - C Murphy
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583, Japan
| | - R Mussa
- INFN Sezione di Torino, I-10125 Torino, Italy
| | - I Nakamura
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - K R Nakamura
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - M Nakao
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - H Nakazawa
- Department of Physics, National Taiwan University, Taipei 10617, Taiwan
| | - Z Natkaniec
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342, Poland
| | - A Natochii
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - G Nazaryan
- Alikhanyan National Science Laboratory, Yerevan 0036, Armenia
| | - C Niebuhr
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - M Niiyama
- Kyoto Sangyo University, Kyoto 603-8555, Japan
| | - N K Nisar
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Nishida
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - K Nishimura
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S Ogawa
- Toho University, Funabashi 274-8510, Japan
| | - Y Onishchuk
- Taras Shevchenko National Univ. of Kiev, Kiev, Ukraine
| | - H Ono
- Niigata University, Niigata 950-2181, Japan
| | - Y Onuki
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - P Oskin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - E R Oxford
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - H Ozaki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - P Pakhlov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
- Moscow Physical Engineering Institute, Moscow 115409, Russian Federation
| | - A Paladino
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - T Pang
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - A Panta
- University of Mississippi, University, Mississippi 38677, USA
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - S Pardi
- INFN Sezione di Napoli, I-80126 Napoli, Italy
| | - H Park
- Kyungpook National University, Daegu 41566, South Korea
| | - S-H Park
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - B Paschen
- University of Bonn, 53115 Bonn, Germany
| | - A Passeri
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
| | - A Pathak
- University of Louisville, Louisville, Kentucky 40292, USA
| | - S Patra
- Indian Institute of Science Education and Research Mohali, SAS Nagar, 140306, India
| | - S Paul
- Department of Physics, Technische Universität München, 85748 Garching, Germany
| | - T K Pedlar
- Luther College, Decorah, Iowa 52101, USA
| | - I Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - R Peschke
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - R Pestotnik
- J. Stefan Institute, 1000 Ljubljana, Slovenia
| | - F Pham
- School of Physics, University of Melbourne, Victoria 3010, Australia
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - L E Piilonen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - G Pinna Angioni
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | | | - T Podobnik
- J. Stefan Institute, 1000 Ljubljana, Slovenia
| | - S Pokharel
- University of Mississippi, University, Mississippi 38677, USA
| | - G Polat
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille, France
| | - V Popov
- National Research University Higher School of Economics, Moscow 101000, Russian Federation
| | - C Praz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - S Prell
- Iowa State University, Ames, Iowa 50011, USA
| | - E Prencipe
- Justus-Liebig-Universität Gießen, 35392 Gießen, Germany
| | - M T Prim
- University of Bonn, 53115 Bonn, Germany
| | - M V Purohit
- Okinawa Institute of Science and Technology, Okinawa 904-0495, Japan
| | - H Purwar
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - N Rad
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - P Rados
- Institute of High Energy Physics, Vienna 1050, Austria
| | - S Raiz
- INFN Sezione di Trieste, I-34127 Trieste, Italy
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - S Reiter
- Justus-Liebig-Universität Gießen, 35392 Gießen, Germany
| | - M Remnev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - I Ripp-Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg, France
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - L B Rizzuto
- J. Stefan Institute, 1000 Ljubljana, Slovenia
| | - S H Robertson
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2, Canada
- McGill University, Montréal, Québec, H3A 2T8, Canada
| | - J M Roney
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2, Canada
- University of Victoria, Victoria, British Columbia, V8W 3P6, Canada
| | - A Rostomyan
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - N Rout
- Indian Institute of Technology Madras, Chennai 600036, India
| | - M Rozanska
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342, Poland
| | - D Sahoo
- Iowa State University, Ames, Iowa 50011, USA
| | - D A Sanders
- University of Mississippi, University, Mississippi 38677, USA
| | - S Sandilya
- Indian Institute of Technology Hyderabad, Telangana 502285, India
| | - A Sangal
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - L Santelj
- J. Stefan Institute, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Y Sato
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - V Savinov
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - B Scavino
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, D-55099 Mainz, Germany
| | - J Schueler
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - C Schwanda
- Institute of High Energy Physics, Vienna 1050, Austria
| | - A J Schwartz
- University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - Y Seino
- Niigata University, Niigata 950-2181, Japan
| | - A Selce
- ENEA Casaccia, I-00123 Roma, Italy
- INFN Sezione di Roma Tre, I-00146 Roma, Italy
| | - K Senyo
- Yamagata University, Yamagata 990-8560, Japan
| | - J Serrano
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille, France
| | - C Sfienti
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, D-55099 Mainz, Germany
| | - J-G Shiu
- Department of Physics, National Taiwan University, Taipei 10617, Taiwan
| | - B Shwartz
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - A Sibidanov
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Simon
- Max-Planck-Institut für Physik, 80805 München, Germany
| | - R J Sobie
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2, Canada
- University of Victoria, Victoria, British Columbia, V8W 3P6, Canada
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978, Israel
| | - A Sokolov
- Institute for High Energy Physics, Protvino 142281, Russian Federation
| | - E Solovieva
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - S Spataro
- INFN Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università di Torino, I-10125 Torino, Italy
| | - B Spruck
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, D-55099 Mainz, Germany
| | - M Starič
- J. Stefan Institute, 1000 Ljubljana, Slovenia
| | - S Stefkova
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - Z S Stottler
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova, Italy
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova, Italy
| | - J Strube
- Pacific Northwest National Laboratory, Richland, Washington, D.C. 99352, USA
| | - M Sumihama
- Gifu University, Gifu 501-1193, Japan
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047, Japan
| | | | - S Y Suzuki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - H Svidras
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - M Tabata
- Chiba University, Chiba 263-8522, Japan
| | - M Takizawa
- J-PARC Branch, KEK Theory Center, High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
- Meson Science Laboratory, Cluster for Pioneering Research, RIKEN, Saitama 351-0198, Japan
- Showa Pharmaceutical University, Tokyo 194-8543, Japan
| | - U Tamponi
- INFN Sezione di Torino, I-10125 Torino, Italy
| | - S Tanaka
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency, Naka 319-1195, Japan
| | - H Tanigawa
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - N Taniguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - F Tenchini
- INFN Sezione di Pisa, I-56127 Pisa, Italy
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa, Italy
| | - R Tiwary
- Tata Institute of Fundamental Research, Mumbai 400005, India
| | - D Tonelli
- INFN Sezione di Trieste, I-34127 Trieste, Italy
| | - E Torassa
- INFN Sezione di Padova, I-35131 Padova, Italy
| | - N Toutounji
- School of Physics, University of Sydney, New South Wales 2006, Australia
| | - K Trabelsi
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - T Tsuboyama
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - I Ueda
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - S Uehara
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - Y Uematsu
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - T Uglov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
- National Research University Higher School of Economics, Moscow 101000, Russian Federation
| | - K Unger
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe, Germany
| | - Y Unno
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763, South Korea
| | - K Uno
- Niigata University, Niigata 950-2181, Japan
| | - S Uno
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - P Urquijo
- School of Physics, University of Melbourne, Victoria 3010, Australia
| | - Y Ushiroda
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193, Japan
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - Y V Usov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - S E Vahsen
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | | | - G S Varner
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Vinokurova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - L Vitale
- INFN Sezione di Trieste, I-34127 Trieste, Italy
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste, Italy
| | - A Vossen
- Duke University, Durham, North Carolina 27708, USA
| | - E Waheed
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - H M Wakeling
- McGill University, Montréal, Québec, H3A 2T8, Canada
| | - E Wang
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - M-Z Wang
- Department of Physics, National Taiwan University, Taipei 10617, Taiwan
| | - X L Wang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443, China
| | - A Warburton
- McGill University, Montréal, Québec, H3A 2T8, Canada
| | - M Watanabe
- Niigata University, Niigata 950-2181, Japan
| | - M Welsch
- University of Bonn, 53115 Bonn, Germany
| | - C Wessel
- University of Bonn, 53115 Bonn, Germany
| | - J Wiechczynski
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342, Poland
| | - E Won
- Korea University, Seoul 02841, South Korea
| | - X P Xu
- Soochow University, Suzhou 215006, China
| | - B D Yabsley
- School of Physics, University of Sydney, New South Wales 2006, Australia
| | - S Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - W Yan
- University of Science and Technology of China, Hefei 230026, China
| | - S B Yang
- Korea University, Seoul 02841, South Korea
| | - H Ye
- Deutsches Elektronen-Synchrotron, 22607 Hamburg, Germany
| | - J Yelton
- University of Florida, Gainesville, Florida 32611, USA
| | - J H Yin
- Korea University, Seoul 02841, South Korea
| | - K Yoshihara
- Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
| | - Y Yusa
- Niigata University, Niigata 950-2181, Japan
| | - L Zani
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille, France
| | - V Zhilich
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090, Russian Federation
- Novosibirsk State University, Novosibirsk 630090, Russian Federation
| | - Q D Zhou
- Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
- Institute for Advanced Research, Nagoya University, Nagoya 464-8602, Japan
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602, Japan
| | - X Y Zhou
- Liaoning Normal University, Dalian 116029, China
| | - V I Zhukova
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - R Žlebčík
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic
| |
Collapse
|
13
|
Chiu T, Yamamoto C, Niu F, Moon H, Truong TG, Cooper R, Hui R. Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes. Perm J 2021; 25:1. [PMID: 33635760 DOI: 10.7812/tpp/20.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND The programmed death 1 (PD-1) inhibitors may improve survival outcomes of non-small cell lung cancer (NSCLC) patients but are associated with immune-related adverse effects (IRAEs). Management of IRAEs may include immunosuppression (ie, corticosteroids), but there is concern that this may affect efficacy. This study evaluated the influence of IRAEs and immunosuppression for IRAEs on survival outcomes of NSCLC patients treated with PD-1 inhibitors (pembrolizumab and nivolumab). METHODS We retrospectively examined data from Kaiser Permanente Southern and Northern California members diagnosed with NSCLC who received a PD-1 inhibitor from March 1, 2011 to September 30, 2016. Our primary goal was to evaluate the effects and management of IRAEs on survival with PD-1 inhibitors. Electronic database records were used to identify the occurrence of IRAEs, medication utilization, and death. Cox proportional hazard models were used to evaluate variables for association with increased risk of death. RESULTS A total of 662 patients were included in the study (median age = 68 years) (interquartile range 61-74). IRAEs were identified in 18% of patients, of which 62% received immunosuppression. Median overall survival was 10 months (interquartile range = 4 months to not reached). Adjusting for covariates, use of immunosuppression during PD-1 inhibitor treatment was not associated with a significantly higher risk of death (hazard ratio = 1.04, 95% confidence interval = 0.84-1.29), whereas corticosteroid use before initiating PD-1 inhibitor therapy was (hazard ratio = 1.48, 95% confidence interval = 1.14-1.91). CONCLUSIONS In a large, real-world cohort from an integrated healthcare system, use of corticosteroids prior to PD-1 inhibitors was associated with worse survival outcomes, whereas concomitant treatment was not.
Collapse
Affiliation(s)
- Timothy Chiu
- Drug Intelligence & Strategy, Kaiser Permanente California Regions, Oakland
| | - Christopher Yamamoto
- Department of Pharmaceutical Services, Ronald Reagen Medical Center, University of California, Los Angeles
| | - Fang Niu
- Pharmacy Outcomes Research Group, Kaiser Permanente California Regions, Downey
| | - Helen Moon
- Hematology-Oncology, Kaiser Permanente Southern California Region
| | | | - Robert Cooper
- Hematology-Oncology, Kaiser Permanente Southern California Region
| | - Rita Hui
- Pharmacy Outcomes Research Group, Kaiser Permanente California Regions, Oakland
| |
Collapse
|
14
|
Kockert M, Mitdank R, Moon H, Kim J, Mogilatenko A, Moosavi SH, Kroener M, Woias P, Lee W, Fischer SF. Semimetal to semiconductor transition in Bi/TiO 2 core/shell nanowires. Nanoscale Adv 2021; 3:263-271. [PMID: 36131884 PMCID: PMC9419100 DOI: 10.1039/d0na00658k] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 11/20/2020] [Indexed: 06/15/2023]
Abstract
We demonstrate the full thermoelectric and structural characterization of individual bismuth-based (Bi-based) core/shell nanowires. The influence of strain on the temperature dependence of the electrical conductivity, the absolute Seebeck coefficient and the thermal conductivity of bismuth/titanium dioxide (Bi/TiO2) nanowires with different diameters is investigated and compared to bismuth (Bi) and bismuth/tellurium (Bi/Te) nanowires and bismuth bulk. Scattering at surfaces, crystal defects and interfaces between the core and the shell reduces the electrical conductivity to less than 5% and the thermal conductivity to less than 25% to 50% of the bulk value at room temperature. On behalf of a compressive strain, Bi/TiO2 core/shell nanowires show a decreasing electrical conductivity with decreasing temperature opposed to that of Bi and Bi/Te nanowires. We find that the compressive strain induced by the TiO2 shell can lead to a band opening of bismuth increasing the absolute Seebeck coefficient by 10% to 30% compared to bulk at room temperature. In the semiconducting state, the activation energy is determined to |41.3 ± 0.2| meV. We show that if the strain exceeds the elastic limit the semimetallic state is recovered due to the lattice relaxation.
Collapse
Affiliation(s)
- M Kockert
- Novel Materials Group, Humboldt-Universität zu Berlin 10099 Berlin Germany
| | - R Mitdank
- Novel Materials Group, Humboldt-Universität zu Berlin 10099 Berlin Germany
| | - H Moon
- Department of Material Science and Engineering, Yonsei University 03722 Seoul Republic of Korea
| | - J Kim
- Division of Nanotechnology, DGIST 42988 Daegu Republic of Korea
| | - A Mogilatenko
- Ferdinand-Braun-Institut, Leibniz-Institut für Höchstfrequenztechnik 12489 Berlin Germany
| | - S H Moosavi
- Laboratory for Design of Microsystems, University of Freiburg - IMTEK 79110 Freiburg Germany
| | - M Kroener
- Laboratory for Design of Microsystems, University of Freiburg - IMTEK 79110 Freiburg Germany
| | - P Woias
- Laboratory for Design of Microsystems, University of Freiburg - IMTEK 79110 Freiburg Germany
| | - W Lee
- Department of Material Science and Engineering, Yonsei University 03722 Seoul Republic of Korea
| | - S F Fischer
- Novel Materials Group, Humboldt-Universität zu Berlin 10099 Berlin Germany
| |
Collapse
|
15
|
Moon H, Lennon DT, Kirkpatrick J, van Esbroeck NM, Camenzind LC, Yu L, Vigneau F, Zumbühl DM, Briggs GAD, Osborne MA, Sejdinovic D, Laird EA, Ares N. Machine learning enables completely automatic tuning of a quantum device faster than human experts. Nat Commun 2020; 11:4161. [PMID: 32814777 PMCID: PMC7438325 DOI: 10.1038/s41467-020-17835-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 07/16/2020] [Indexed: 11/28/2022] Open
Abstract
Variability is a problem for the scalability of semiconductor quantum devices. The parameter space is large, and the operating range is small. Our statistical tuning algorithm searches for specific electron transport features in gate-defined quantum dot devices with a gate voltage space of up to eight dimensions. Starting from the full range of each gate voltage, our machine learning algorithm can tune each device to optimal performance in a median time of under 70 minutes. This performance surpassed our best human benchmark (although both human and machine performance can be improved). The algorithm is approximately 180 times faster than an automated random search of the parameter space, and is suitable for different material systems and device architectures. Our results yield a quantitative measurement of device variability, from one device to another and after thermal cycling. Our machine learning algorithm can be extended to higher dimensions and other technologies.
Collapse
Affiliation(s)
- H Moon
- Department of Materials, University of Oxford, Parks Road, Oxford, OX1 3PH, UK
| | - D T Lennon
- Department of Materials, University of Oxford, Parks Road, Oxford, OX1 3PH, UK
| | | | - N M van Esbroeck
- Department of Materials, University of Oxford, Parks Road, Oxford, OX1 3PH, UK
- Department of Applied Physics, Eindhoven University of Technology, Eindhoven, MB, 5600, The Netherlands
| | - L C Camenzind
- Department of Physics, University of Basel, Basel, 4056, Switzerland
| | - Liuqi Yu
- Department of Physics, University of Basel, Basel, 4056, Switzerland
| | - F Vigneau
- Department of Materials, University of Oxford, Parks Road, Oxford, OX1 3PH, UK
| | - D M Zumbühl
- Department of Physics, University of Basel, Basel, 4056, Switzerland
| | - G A D Briggs
- Department of Materials, University of Oxford, Parks Road, Oxford, OX1 3PH, UK
| | - M A Osborne
- Department of Engineering, University of Oxford, Walton Well Road, Oxford, OX2 6ED, UK
| | - D Sejdinovic
- Department of Statistics, University of Oxford, 24-29 St Giles, Oxford, OX1 3LB, UK
| | - E A Laird
- Department of Physics, Lancaster University, Lancaster, LA1 4YB, UK
| | - N Ares
- Department of Materials, University of Oxford, Parks Road, Oxford, OX1 3PH, UK.
| |
Collapse
|
16
|
Moon H, Kim D, Donahue L, White A. 785 Phenotypic plasticity of cutaneous squamous cell carcinoma mediated by cyclooxygenase-2. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Moon H, Lee H, Jeong H. P-60 Tolerability of adjuvant chemotherapy with TS-1 or XELOX regimen in elderly patients with stage II or III gastric cancer after D2 gastrectomy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Lee J, Seo M, Moon H, Kim D, Lee H, Chung J, Kim H. 3:18 PM Abstract No. 229 Antitumor effect of transarterial chemoembolization using doxorubicin-albumin nanoparticle loaded lipid microbubbles combined with ultrasound-targeted activation on VX2 rabbit liver tumors. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
19
|
Moon H, Jeong H. Self-expandable metal stent (SEMS) for esophageal-gastric junction versus pyloric area obstruction in advanced gastric cancer patients: a retrospective, comparative, single-center study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Lee H, Kim J, Kang S, Moon H, Sung J, Jeong H. Treatment efficacy of endoscopic submucosal dissection for papillary adenocarcinoma-type early gastric cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Yu EY, Fling S, Salim B, Sweis RF, Chatta GS, Jain RK, Delacroix SE, Moon H, Lacroix A, Kaiser JC, Sharon E, Cheever MA, Pachynski R. A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.tps4586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS4586 Background: Atezolizumab is a regulatory-approved PD-L1 antagonistic antibody for the post-platinum mUC setting. Responses to atezolizumab are highly efficacious in a subset of patients, but suboptimal or absent in most patients. IL-7 (CYT107) is a homeostatic growth factor that promotes proliferation, differentiation, and survival of T lymphocytes. We recently demonstrated CYT107 significantly increases peripheral absolute lymphocyte and T cell numbers in metastatic castration-resistant prostate cancer patients when administered after sipuleucel-T. We hypothesize expansion of T cells by CYT107 may improve responses to PD-L1 inhibition. To test this hypothesis, we designed a randomized trial (NCT03513952) in mUC comparing the combination of CYT107 and atezolizumab to atezolizumab alone. Methods: Patients with ECOG PS ≤2 and RECIST v1.1 measurable mUC with disease recurrence after platinum-based chemotherapy are eligible. A safety run-in of 6 patients with staggered enrollment to atezolizumab plus CYT107 will be followed by randomization if <2 patients experience a DLT. An additional 48 patients will then be randomized 1:1 to atezolizumab 1200 mg IV q3wks with or without CYT107 10 ug/kg IM qwk X 4, started 1 wk before atezolizumab. The primary endpoint is RECIST v1.1 ORR, with H0 14.8% and HA 45%, one-sided α 0.10; power 88%. An interim futility analysis will be performed after 24 randomized patients have their first disease assessment; cessation of the trial will occur if an O’Brien-Fleming futility boundary of <-0.0063 in the ORR scale is observed between the experimental and control arm. Secondary endpoints include clinical benefit rate, PFS, DOR, OS, results by PD-L1 expression stratification, and safety. Exploratory correlative evaluations of tumor-infiltrating immune cells, interferon γ expression, inflammatory gene expression, ELISPOT, T cell receptor sequencing, serum metabolite levels, gut microbiome, and PK analyses will be performed. Current state: Trial accrual has begun and is anticipated to complete around mid-2020. Clinical trial information: NCT03513952.
Collapse
Affiliation(s)
| | - Steven Fling
- Fred Hutchinson Cancer Research Center, Seattle, WA
| | | | | | | | - Rohit K. Jain
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | | | | | | | | | | | | | - Russell Pachynski
- Division of Oncology, Washington University Medical School, St. Louis, MO
| |
Collapse
|
22
|
Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM SM registry. J Immunother Cancer 2019; 7:84. [PMID: 30917871 PMCID: PMC6437874 DOI: 10.1186/s40425-019-0567-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 03/14/2019] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inhibitory immunotherapy and tyrosine kinase inhibitor therapy, but have not been applied extensively to patients receiving high dose interleukin-2 (HD IL-2) immunotherapy. METHODS Survival of 810 mRCC patients treated from 2006 to 2017 with high dose IL-2 (aldesleukin) and enrolled in the PROCLAIMSM registry data base was assessed utilizing the International Metastatic RCC Database Consortium (IMDC) risk criteria. Median follow-up is 23.4 months (mo.) (range 0.2-124 mo.). Subgroup evaluations were performed by separating patients by prior or no prior therapy, IL-2 alone, or therapy subsequent to IL-2. Some patients were in two groups. We will focus on the 356 patients who received IL-2 alone, and evaluate outcome by risk factor categories. RESULTS Among the 810 patients, 721 were treatment-naïve (89%) and 59% were intermediate risk. Overall, of the 249 patients with favorable risk, the median overall survival (OS) is 63.3 mo. and the 2-year OS is 77.6%. Of 480 patients with intermediate risk, median OS is 42.4 mo., 2-year OS 68.2%, and of 81 patients with poor risk, median OS 14 mo., 2-year OS 40.4%. Among those who received IL-2 alone (356 patients), median OS is 64.5, 57.6, and 14 months for favorable, intermediate and poor risk categories respectively. Two year survival among those treated only with HD IL-2 is 73.4, 63.7 and 39.8%, for favorable, intermediate and poor risk categories respectively. CONCLUSIONS Among mRCC patients treated with HD IL-2, all risk groups have median and 2-year survival consistent with recent reports of checkpoint or targeted therapies for mRCC. Favorable and intermediate risk (by IMDC) patients treated with HD IL-2 have longer OS compared with poor risk patients, with most durable OS observed in favorable risk patients. Favorable risk patients treated with HD IL-2 alone have a 2-year OS of 74%. These data continue to support a recommendation for HD IL-2 for patients with mRCC who meet eligibility criteria. TRIAL REGISTRATION PROCLAIM, NCT01415167 was registered with ClinicalTrials.gov on August 11, 2011, and initiated for retrospective data collection until 2006, and prospective data collection ongoing since 2011.
Collapse
Affiliation(s)
| | | | - J. I. Clark
- Loyola University Medical Center, Maywood, IL USA
| | - A. Alva
- University of Michigan, Ann Arbor, MI USA
| | | | - B. Curti
- Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR USA
| | - Neeraj Agarwal
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA
| | - R. Hauke
- Nebraska Cancer Specialist, Omaha, NE USA
| | - K. M. Mahoney
- Beth Israel Deaconess Medical Center, Boston, MA USA
| | - H. Moon
- Southern California Permanente Medical Group, Pasadena, CA USA
| | - J. Treisman
- Medical College of Wisconsin, Milwaukee, WI USA
| | - S. S. Tykodi
- University of Washington and Fred Hutchinson Cancer Center, Seattle, WA USA
| | - G. Daniels
- University of California San Diego, San Diego, CA USA
| | | | | | - H. Kaufman
- Massachusetts General Hospital, Boston, MA USA
| | - N. Gregory
- Prometheus Laboratories, San Diego, CA USA
| | | |
Collapse
|
23
|
B N, Shim WG, Balathanigaimani MS, Moon H. Retraction notice: Influence of compressing pressure on macro void formation carbon monolith for methane adsorption. Mong J Chem 2019. [DOI: 10.5564/mjc.v19i45.1089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
RETRACTION NOTICEOn 21rd February 2019, the Editorial Board of the Mongolian Journal of Chemistry decided to retract this article entitled "Influence of compressing pressure on macro void formation of carbon monolith for methane adsorption" because of an authorship dispute. The article was originally published in Vol.18 No.44 2017 pp.24-35. doi: https://doi.org/10.5564/mjc.v18i44.934
Collapse
|
24
|
Moon H, Sears J, Rote S, Haley WE. THE ROLE OF CARE RECIPIENT NATIVITY STATUS IN THEIR CAREGIVERS’ QUALITY OF LIFE. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Moon
- University of Louisville, louisville, Kentucky, United States
| | - J Sears
- University of Louisville, Louisville, KY, USA
| | - S Rote
- University of Louisville, Louisville, KY, USA
| | - W E Haley
- University of South Florida, Tampa, FL, USA
| |
Collapse
|
25
|
Park Y, Woo, M C, Moon H, Moon B, You S. P05.33 Extra-articular tenosynovial giant cell tumor of diffuse type in the temporal area with brain parenchymal invasion. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Park
- Chungbuk National university, Cheongju, Korea, Republic of
| | - C Woo, M
- Chungbuk National university, Cheongju, Korea, Republic of
| | - H Moon
- Chungbuk National university, Cheongju, Korea, Republic of
| | - B Moon
- Chungbuk National university, Cheongju, Korea, Republic of
| | - S You
- Chungbuk National university, Cheongju, Korea, Republic of
| |
Collapse
|
26
|
Park J, Moon H, Kwon I, Kim J, Kang S, Lee E, Kim S, Sung J, Lee B, Jeong H. Usefulness of colonic tattooing using ICG in patients with colorectal tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Moon H, Kang S, Sung J, Jeong H. Endoscopic prediction of tumor invasion depth in early gastric signet ring cell carcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Fishman MN, Clark JI, Alva AS, Curti BD, Agarwal N, Hauke RJ, Mahoney KM, Moon H, Treisman J, Tykodi S, Daniels GA, Morse M, Wong MK, Kaufman H, Gregory NC, Dutcher JP. Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.4578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Brendan D. Curti
- Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR
| | - Neeraj Agarwal
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | | | - Helen Moon
- Kaiser Permanente Southern California, Riverside, CA
| | | | - Scott Tykodi
- Fred Hutchinson Cancer Research Center, Seattle, WA
| | | | | | | | | | | | | |
Collapse
|
29
|
Truong TG, Moon H, Chiu T, Yamamoto C, Spence MM, Kavecansky J, Niu F, Hui RL. Immune-related adverse events (IRAE) of elderly patients (PTS) with advanced melanoma (AMEL) treated with checkpoint inhibitors (CI) in a community setting: The experience (EXP) at Kaiser Permanente (KP) California. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e21583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Helen Moon
- Kaiser Permanente Southern California, Riverside, CA
| | - Timothy Chiu
- Kaiser Permanente Northern California, Oakland, CA
| | | | | | | | - Fang Niu
- Kaiser Permanente Southern California, Pasadena, CA
| | - Rita L. Hui
- Kaiser Permanente Northern California, Oakland, CA
| |
Collapse
|
30
|
Moon H, Gudmundsson L, Seneviratne SI. Drought Persistence Errors in Global Climate Models. J Geophys Res Atmos 2018; 123:3483-3496. [PMID: 29938145 PMCID: PMC5993269 DOI: 10.1002/2017jd027577] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 02/27/2018] [Accepted: 03/03/2018] [Indexed: 06/08/2023]
Abstract
The persistence of drought events largely determines the severity of socioeconomic and ecological impacts, but the capability of current global climate models (GCMs) to simulate such events is subject to large uncertainties. In this study, the representation of drought persistence in GCMs is assessed by comparing state-of-the-art GCM model simulations to observation-based data sets. For doing so, we consider dry-to-dry transition probabilities at monthly and annual scales as estimates for drought persistence, where a dry status is defined as negative precipitation anomaly. Though there is a substantial spread in the drought persistence bias, most of the simulations show systematic underestimation of drought persistence at global scale. Subsequently, we analyzed to which degree (i) inaccurate observations, (ii) differences among models, (iii) internal climate variability, and (iv) uncertainty of the employed statistical methods contribute to the spread in drought persistence errors using an analysis of variance approach. The results show that at monthly scale, model uncertainty and observational uncertainty dominate, while the contribution from internal variability is small in most cases. At annual scale, the spread of the drought persistence error is dominated by the statistical estimation error of drought persistence, indicating that the partitioning of the error is impaired by the limited number of considered time steps. These findings reveal systematic errors in the representation of drought persistence in current GCMs and suggest directions for further model improvement.
Collapse
Affiliation(s)
- H. Moon
- Institute for Atmospheric and Climate ScienceETH ZurichZurichSwitzerland
| | - L. Gudmundsson
- Institute for Atmospheric and Climate ScienceETH ZurichZurichSwitzerland
| | - S. I. Seneviratne
- Institute for Atmospheric and Climate ScienceETH ZurichZurichSwitzerland
| |
Collapse
|
31
|
B N, Shim WG, Balathanigaimani MS, Moon H. Influence of compressing pressure on macro void formation of carbon monolith for methane adsorption. Mong J Chem 2018. [DOI: 10.5564/mjc.v18i44.934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Carbon monoliths for adsorbed natural gas (ANG) storage were prepared from Mongolian anthracite-based activated carbons using carboxy-methyl cellulose as a binder under different compressing pressures. Nitrogen adsorption/desorption experiments were carried out to obtain the specific surface area, pore volume, and pore size distribution of the monoliths. Methane adsorption experiments on the carbon monoliths were conducted at different temperatures and pressures up to around 3.5 MPa in a high pressure volumetric adsorption apparatus. As expected, adsorption results indicated that the methane adsorption capacity of the carbon monoliths increased with increasing specific surface area and packing density. The maximum volumetric adsorption of methane was observed as 163 V/V at 293 K and 3.5 MPa on a carbon monolith sample, PMAC1/2-3-65, that does not have the highest specific surface area but relatively high packing density comparing with other monoliths, which implies that two physical properties contribute contradictorily to the methane adsorption capacity. Based on experimental results, the carbon monoliths prepared from Mongolian anthracite-based activated carbons can be promising media for ANG storage application.
Collapse
|
32
|
Cooper RM, Yamamoto C, Truong TG, Niu F, Moon H, Spence MM, Chan J, Chiu T, Hui RL. Use of immune checkpoint inhibitors in a community practice within a vertically integrated health care system. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.5_suppl.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
130 Background: Four immune checkpoint inhibitors have been FDA approved from 2011 to 2016. Immune checkpoint inhibitors function differently from chemotherapy and have different benchmarks for response as well as different side effect profiles. This report examines how oncologists in two large medical groups have introduced these new treatments into their practices. Kaiser Permanente is a large HMO which insures 8.5 million members in the state of California and has an exclusive contract with 2 large medical groups to care for its members. There are over 200 medical oncologists caring for KP members practice at over 35 medical centers. The care of the KP members has been documented in an EPIC based medical record systems since 2006. Methods: The Pharmacy Research Outcomes Group has conducted a retrospective cohort study looking at patients who initiated Checkpoint inhibitors between March 2011 and September 2016 for this review and followed the patients till December 2016. Electronically available data collected for this review includes patient characteristics such as but not exclusive to: cancer diagnosis, previous therapies, current therapies, age, sex, ethnicity, immune related adverse events (IRAEs) proxy by diagnosis code, duration of immunotherapy, use of systemic steroids, Charlson Co-morbity Index and survival. Results: We reviewed a total of 1760 users of Checkpoint Inhibitors. We show the uptake of this class of medications aligns with approved checkpoint inhibitors and the new indications of these agents. We were able to electronically pull medical information and define IRAEs. Our data closely matches the expected incidence of IRAEs as reported in clinical trials. We were also able to monitor the use of steroids in response to these events. Conclusions: The ability to collect and track this information has allowed the group to better understand patient selection practices as well as management practices in the community practice setting.
Collapse
Affiliation(s)
| | | | | | | | - Helen Moon
- Kaiser Permanente Southern California, Riverside, CA
| | | | | | - Timothy Chiu
- Kaiser Permanente Northern California, Oakland, CA
| | - Rita L. Hui
- Kaiser Permanente Northern California, Oakland, CA
| |
Collapse
|
33
|
Truong TG, Yamamoto C, Chiu T, Niu F, Spence MM, Chan J, Cooper RM, Moon H, Hui RL. Immune-related adverse events (IrAE) of elderly patients (pts) receiving PD-1 or PDL-1 inhibitors (PDIs) in a community-oncology setting: The experience at Kaiser Permanente California. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.5_suppl.124] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
124 Background: Checkpoint inhibitors (CI) are rapidly changing the treatment (Tx) landscape across multiple cancers. They have brought with them a new set of immune-related toxicities and complications . Currently, our knowledge of irAEs has been largely informed by clinical trials enrolling younger and fitter pts. In this study, we report the experience of our large community practice, where many elderly pts of diverse backgrounds received PDIs. Methods: We conducted a retrospective cohort study, including pts who were ≥65 years old (yo) and had received PDIs between FDA approval in 2014 and September 2016, with follow-up through December 2016. Through data-mining of our electronic medical record, we evaluated the incidence of irAE and Tx outcomes, stratified by age, ethnicity, gender, co-morbidity index, and tumor subtype. Results: There were 776 pts included in the analysis. 58% were male and 29% were non-Caucasian. 83% were ages 65 to 79 yo and 17% were ≥80 yo (range 80-94 yo). 28 % of pts had a CCI > 5. Over 55% received PDIs for non-small cell lung cancer (NSCLC), followed by 12% for melanoma. 65-79 yo pts experienced similar incidence of irAE compared to pts ≥80 yo (14% vs 18%, p = 0.26). Notably, incidence was similar for gastrointestinal, pulmonary, and endocrine toxicity, though pts ≥80 yo experienced higher incidence of dermatologic toxicity (p = 0.01). Pts 65-79 yo received PDIs for median 3.3 months (mos), while pts ≥80 yo were on Tx for median 2.8 mos.The rate of irAE that resulted in health care utilization were noted in 15% of pts. Time to onset of irAE was similar between the 2 age groups (p = 0.40). Unadjusted hazard ratio (HR) for survival at the end of study was similar for pts 65-79 yo and ≥80 yo who had melanoma (HR = 0.99, p = 0.97) or NSCLC (HR = 1.32, p = 0.12). Conclusions: This is the first report of Tx outcomes with PDI use in elderly pts in a real-world setting. We found irAE rates and Tx outcomes to be similar for pts age 65-79 yo and those ≥ 80 yo. With rising cancer incidence among an ageing population, it is important for the oncology community to understand how CI therapy affects older pt groups to improve their cancer outcomes.
Collapse
Affiliation(s)
| | | | - Timothy Chiu
- Kaiser Permanente Northern California, Oakland, CA
| | - Fang Niu
- Kaiser Permanente Southern California, Pasadena, CA
| | | | | | | | - Helen Moon
- Kaiser Permanente Southern California, Riverside, CA
| | - Rita L. Hui
- Kaiser Permanente Northern California, Oakland, CA
| |
Collapse
|
34
|
Moon H, Sim S. A retrospective study on peritoneal fluid analysis profiles to predict bacterascites associated with malignant ascites. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx676.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Moon H, Rote S. FACTORS THAT CONTRIBUTE TO REMAINING IN THE COMMUNITY AMONG OLDER ADULTS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- H. Moon
- University of Louisville, Louisville, Kentucky
| | - S. Rote
- University of Louisville, Louisville, Kentucky
| |
Collapse
|
36
|
Eom H, Jung J, Lee H, Yun T, Lee E, Moon H, Joo J, Park W, Choi M, Lee J, Lee J. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_69] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- H. Eom
- Center for Hematologic Malignancy; National Cancer Center; Goyang South Korea
| | - J. Jung
- Department of Cancer Biomedical Science; Graduate School of Cancer Science and Policy, National Cancer Center; Goyang South Korea
| | - H. Lee
- Center for Hematologic Malignancy; National Cancer Center; Goyang South Korea
| | - T. Yun
- Department of Internal Medicine; National Cancer Center; Goyang South Korea
| | - E. Lee
- Center for Hematologic Malignancy; National Cancer Center; Goyang South Korea
| | - H. Moon
- Department of Internal Medicine; National Cancer Center; Goyang South Korea
| | - J. Joo
- 5Biometrics Research Branch; Research Institute, National Cancer Center; Goyang South Korea
| | - W. Park
- Department of Pathology; National Cancer Center; Goyang South Korea
| | - M. Choi
- Department of Hematology and Medical Oncology; Seoul National University Hospital; Seoul South Korea
| | - J. Lee
- Division of Hematology and Medical Oncology; Seoul National University Bundang Hospital; Seongnam South Korea
| | - J. Lee
- Division of Hematology and Medical Oncology; Seoul National University Bundang Hospital; Seongnam South Korea
| |
Collapse
|
37
|
Javier F, Thinh D, Sriraj W, Mansor M, Irawan C, Yusak S, Kurnianda J, Nguyen Y, Ong-Cornel A, Hadjiat Y, Moon H. 522O_PR Analgesia for cancer pain in Southeast Asia (SEA): Prescription patterns, pain control, treatment satisfaction and quality of life (QoL). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw599.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Moon H, Kim S, Park G, Koo J. Profuse Vaginal Discharge May Equally Suggest Adenoma Malignum and Lobular Endocervical Glandular Hyperplasia (LEGH), But Same Cover, Different Story. J Minim Invasive Gynecol 2016; 22:S147. [PMID: 27678817 DOI: 10.1016/j.jmig.2015.08.527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- H Moon
- Center for Minimally Invasive Surgery, Department of Obstetrics and Gynecology, Good Moonhwa Hospital, Busan, Korea
| | - S Kim
- Center for Minimally Invasive Surgery, Department of Obstetrics and Gynecology, Good Moonhwa Hospital, Busan, Korea
| | - G Park
- Center for Minimally Invasive Surgery, Department of Obstetrics and Gynecology, Good Moonhwa Hospital, Busan, Korea
| | - J Koo
- Center for Minimally Invasive Surgery, Department of Obstetrics and Gynecology, Good Moonhwa Hospital, Busan, Korea
| |
Collapse
|
39
|
Abstract
Algorithms based on principal component analysis (PCA) form the basis of numerous studies in the psychological and algorithmic face-recognition literature. PCA is a statistical technique and its incorporation into a face-recognition algorithm requires numerous design decisions. We explicitly state the design decisions by introducing a generic modular PCA-algorithm. This allows us to investigate these decisions, including those not documented in the literature. We experimented with different implementations of each module, and evaluated the different implementations using the September 1996 FERET evaluation protocol (the de facto standard for evaluating face-recognition algorithms). We experimented with (i) changing the illumination normalization procedure; (ii) studying effects on algorithm performance of compressing images with JPEG and wavelet compression algorithms; (iii) varying the number of eigenvectors in the representation; and (iv) changing the similarity measure in the classification process. We performed two experiments. In the first experiment, we obtained performance results on the standard September 1996 FERET large-gallery image sets. In the second experiment, we examined the variability in algorithm performance on different sets of facial images. The study was performed on 100 randomly generated image sets (galleries) of the same size. Our two most significant results are (i) changing the similarity measure produced the greatest change in performance, and (ii) that difference in performance of ±10% is needed to distinguish between algorithms.
Collapse
Affiliation(s)
- H Moon
- Department of Electrical and Computer Engineering, State University of New York at Buffalo, Amherst, NY 14260, USA.
| | | |
Collapse
|
40
|
Moon H, Cong M. Predictive models of cytotoxicity as mediated by exposure to chemicals or drugs. SAR QSAR Environ Res 2016; 27:455-468. [PMID: 27442234 DOI: 10.1080/1062936x.2016.1208272] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Accepted: 06/28/2016] [Indexed: 06/06/2023]
Abstract
Predicting cytotoxicity is a challenging task because of the complex biological mechanisms behind it. Cytotoxicity due to toxin - biologically produced poison - is known to play a substantial role in a disease process. Two objectives in this research are to derive robust general predictive cytotoxicity models to minimize unnecessary toxicity. The first objective is to build accurate predictive statistical models for cytotoxicity data based on lymphoblastoid cell lines obtained from in vitro studies. This could be an important step for accomplishing a goal in biomedecial/biophamarceutical research, by obtaining the best medical outcomes by minimizing toxicity in regard to a person's genetic profile. The second objective is to build predictive models to predict population-level cytotoxicity for unknown compounds based on chemical structural features. These two objectives were accomplished by a proposed variable selection process, the random forests, and the least absolute shrinkage and selection operator method. We achieved an excellent prediction result with the random forests algorithm using SNP markers from the proposed approach, having the smallest root mean squared error among the teams which participated in the DREAM Toxicogenetics Challenge. Since chemical compounds for drugs have great influence on human health, the predictive statistical models for these objectives could be helpful to government agencies in relevant decision-making.
Collapse
Affiliation(s)
- H Moon
- a Department of Mathematics and Statistics , California State University , Long Beach , CA , USA
| | - M Cong
- a Department of Mathematics and Statistics , California State University , Long Beach , CA , USA
| |
Collapse
|
41
|
Moon H, Kim Y, Wi JM, Chi M. Morphological characteristics and clinical manifestations of orbital emphysema caused by isolated medial orbital wall fractures. Eye (Lond) 2016; 30:582-7. [PMID: 26795415 DOI: 10.1038/eye.2015.285] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Accepted: 12/08/2015] [Indexed: 11/09/2022] Open
Abstract
PURPOSE To investigate the morphological characteristics and clinical manifestations of orbital emphysema in patients with isolated medial orbital wall fractures. METHODS This was a retrospective observational case series of 348 orbits of 348 patients with isolated medial orbital wall fractures. Medical charts were reviewed, and computed tomographic (CT) images were examined to determine the morphological characteristics of orbital emphysema. RESULTS Orbital emphysema was detected in 70 orbits (20.1%). Large and communited type fracture was related with the presence of orbital emphysema (P<0.05). Orbital air pockets were detected in medial or superior extraconal orbital segment in all cases with orbital emphysema. Swollen eyelid with crepitus (90.0%) and supraduction limitation (31.4%) were developed with orbital emphysema. All cases with supraduction limitation accompanied with superior extraconal orbital emphysema and superior rectus muscle deviation, and these eyes were fully recovered with conservative management without surgery. CONCLUSIONS Orbital emphysema can be a cause of ocular motility restriction following orbital wall fracture. If supraduction limitation is noted with isolated medial wall fracture and superior orbital emphysema with superior rectus muscle deviation is detected by CT scan, conservative management can be a good choice for spontaneous recovery delaying the surgery.
Collapse
Affiliation(s)
- H Moon
- Yeonsu Ever Bright Eye Clinic, Incheon, Korea
| | - Y Kim
- Department of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea
| | - J M Wi
- Department of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea
| | - M Chi
- Department of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea
| |
Collapse
|
42
|
Kim Y, Park K, Chung P, Moon H, Suh B, Yoon W. Right-side propensity of cardiogenic emboli in acute ischemic stroke with atrial fibrillation. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.1374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
43
|
Kim SA, Moon H, Lee K, Rhee MS. Bactericidal effects of triclosan in soap both in vitro and in vivo. J Antimicrob Chemother 2015; 70:3345-52. [PMID: 26374612 DOI: 10.1093/jac/dkv275] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Accepted: 08/10/2015] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES On December 2013, the US FDA proposed a rule stating that manufacturers must provide data to demonstrate that antibacterial soap is more effective than plain soap or water. The objective of the present study was to examine the in vitro and in vivo bactericidal effect of triclosan (the most widely used antiseptic agent in soap) in soap. METHODS Twenty bacterial strains (proposed by the FDA) were exposed to plain and antibacterial soaps (the same formulation as plain soap, but containing 0.3% triclosan) for 20 s at 22°C (room temperature) and 40°C (warm temperature). The temperature and time were selected to simulate the hand washing conditions and procedures used by consumers. The triclosan concentration of 0.3% is the maximum allowed by law. The decontamination efficacy of plain soap and antibacterial soap was also examined in vivo: the hands of volunteers were artificially inoculated with Serratia marcescens. RESULTS There was no significant difference (P > 0.05) in bactericidal activity between plain soap and antibacterial soap at either test temperature. However, antibacterial soap showed significantly greater bactericidal effects after 9 h. These results suggest that although triclosan-containing soap does have antibacterial activity, the effects are not apparent during the short time required for hand washing. CONCLUSIONS Antibacterial soap containing triclosan (0.3%) was no more effective than plain soap at reducing bacterial contamination when used under 'real-life' conditions. The present study provides practical information that may prove useful for both industry and governments.
Collapse
Affiliation(s)
- S A Kim
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 136-713, Republic of Korea
| | - H Moon
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 136-713, Republic of Korea
| | - K Lee
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 136-713, Republic of Korea
| | - M S Rhee
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 136-713, Republic of Korea
| |
Collapse
|
44
|
Seong Y, Moon H, Park S. V-068THORACOSCOPIC THYMECTOMY IN A PATIENT WITH RIGHT AORTIC ARCH. Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Cooney D, Moon H, Liu Y, Miller RT, Perzynski A, Watts B, Drawz PE. A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial. BMC Nephrol 2015; 16:56. [PMID: 25881226 PMCID: PMC4405859 DOI: 10.1186/s12882-015-0052-2] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Accepted: 04/07/2015] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Primary care providers do not routinely follow guidelines for the care of patients with chronic kidney disease (CKD). Multidisciplinary efforts may improve care for patients with chronic disease. Pharmacist based interventions have effectively improved management of hypertension. We performed a pragmatic, randomized, controlled trial to evaluate the effect of a pharmacist based quality improvement program on 1) outcomes for patients with CKD and 2) adherence to CKD guidelines in the primary care setting. METHODS Patients with moderate to severe CKD receiving primary care services at one of thirteen community-based Veterans Affairs outpatient clinics were randomized to a multifactorial intervention that included a phone-based pharmacist intervention, pharmacist-physician collaboration, patient education, and a CKD registry (n = 1070) or usual care (n = 1129). The primary process outcome was measurement of parathyroid hormone (PTH) during the one year study period. The primary clinical outcome was blood pressure (BP) control in subjects with poorly controlled hypertension at baseline. RESULTS Among those with poorly controlled baseline BP, there was no difference in the last recorded BP or the percent at goal BP during the study period (42.0% vs. 41.2% in the control arm). Subjects in the intervention arm were more likely to have a PTH measured during the study period (46.9% vs. 16.1% in the control arm, P <0.001) and were on more classes of antihypertensive medications at the end of the study (P = 0.02). CONCLUSIONS A one-time pharmacist based intervention proved feasible in patients with CKD. While the intervention did not improve BP control, it did improve guideline adherence and increased the number of antihypertensive medications prescribed to subjects with poorly controlled BP. These findings can inform the design of quality improvement programs and future studies which are needed to improve care of patients with CKD. TRIAL REGISTRATION ClinicalTrials.gov: NCT01290614.
Collapse
Affiliation(s)
| | - Helen Moon
- Louis Stokes Cleveland VAMC, Cleveland, OH, USA.
| | - Yang Liu
- Case Western Reserve University, Cleveland, OH, USA.
| | | | - Adam Perzynski
- Case Western Reserve University, Cleveland, OH, USA. .,MetroHealth Medical Center, Cleveland, OH, USA.
| | - Brook Watts
- Louis Stokes Cleveland VAMC, Cleveland, OH, USA. .,Case Western Reserve University, Cleveland, OH, USA.
| | - Paul E Drawz
- Division of Renal Diseases & Hypertension, University of Minnesota, 717 Delaware Street SE, Office 353E, Minneapolis, MN, 55414, USA.
| |
Collapse
|
46
|
Cho S, Park K, Moon H. EHMTI-0300. Clinical application of korean version of the international classification of headache disorders, 3rd edition, beta version in university hospitals. J Headache Pain 2014. [PMCID: PMC4180939 DOI: 10.1186/1129-2377-15-s1-d6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
47
|
Yang Y, Im S, Keam B, Lee K, Kim T, Oh D, Han S, Kim T, Han W, Moon H, Park I, Noh D. Clinical Usefulness of Ajcc Response Criteria in Stage Ii/Iii Breast Cancer Patients Who Treated with Long Course Neoadjuvant Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu328.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Cho Y, Moon H, Lee Y, Song M. Effects of pregabalin on patients with hypnotic dependent insomnia. Sleep Med 2013. [DOI: 10.1016/j.sleep.2013.11.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Kim TS, Lee HS, Oh SH, Moon H, Lee S, Song S, Shin M, Park JB, Kim SJ, Joh JW, Lee SK. Optimal device and method for transportation of isolated porcine islet. Transplant Proc 2013; 45:3097-101. [PMID: 24157043 DOI: 10.1016/j.transproceed.2013.08.083] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
INTRODUCTION We investigated the optimal method for transportation of isolated porcine islets from an isolation facility to a transplant hospital or research center in terms of temperature, oxygen supply, and shaking effect. METHODS Commercially available insulator boxes with thermoregulators exposed for 5 hours under two external temperatures (4°C and 37°C) were monitored using HOBO temperature loggers. To find the optimal transport device, we compared islet counts, viability, quality, and function in conical tubes, gas-permeable bags (GPB) and gas-permeable flasks (GPF) after 1, 3 and 5 hours. To evaluate the effects of shaking on islets, we also analyzed the difference between a control and a shaking group in each device with time. RESULTS Commercially available Styrofoam insulators with thermoregulators maintained the internal temperature near the target. Islet recovery rate for GPF, which was higher than other devices, was maintained, while those decreased with time for conical tube and GPB containers adenosine diphosphate/adenosine triphosphate (ADP/ATP) ratio for GPF was lower than other devices, albeit not significantly fluoroscein acrimide/propidium iodide (AO/PI) ratio for GPF was higher than other devices after 5 hours. Glucose stimulated index was not different among the devices. In comparison with the control group, shaking yielded comparable islet survival, viability and function. CONCLUSION Our study demonstrated that the use of commercially available insulator boxes with thermoregulators maintained internal temperature close to the target value and that GPF was more favorable for islet oxygenation during transportation. This study also suggested negligible impact of shaking on isolated porcine islets during transportation.
Collapse
Affiliation(s)
- T-S Kim
- Department of Surgery, Samsung Medical Center, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Lê Cao KA, Winterford C, Coward JI, Ling MT, Craik DJ, Parton RG, Russell PJ, Hill MM. PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene 2013; 33:3561-70. [PMID: 23934189 DOI: 10.1038/onc.2013.315] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Revised: 06/08/2013] [Accepted: 06/11/2013] [Indexed: 12/15/2022]
Abstract
Caveolin-1 has a complex role in prostate cancer and has been suggested to be a potential biomarker and therapeutic target. As mature caveolin-1 resides in caveolae, invaginated lipid raft domains at the plasma membrane, caveolae have been suggested as a tumor-promoting signaling platform in prostate cancer. However, caveola formation requires both caveolin-1 and cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, non-malignant and malignant prostate tissues. We found that caveolin-1 was induced without the presence of cavin-1 in advanced prostate carcinoma, an expression pattern mirrored in the PC-3 cell line. In contrast, normal prostate epithelia expressed neither caveolin-1 nor cavin-1, while prostate stroma highly expressed both caveolin-1 and cavin-1. Utilizing PC-3 cells as a suitable model for caveolin-1-positive advanced prostate cancer, we found that cavin-1 expression in PC-3 cells inhibits anchorage-independent growth, and reduces in vivo tumor growth and metastasis in an orthotopic prostate cancer xenograft mouse model. The expression of α-smooth muscle actin in stroma along with interleukin-6 (IL-6) in cancer cells was also decreased in tumors of mice bearing PC-3-cavin-1 tumor cells. To determine whether cavin-1 acts by neutralizing caveolin-1, we expressed cavin-1 in caveolin-1-negative prostate cancer LNCaP and 22Rv1 cells. Caveolin-1 but not cavin-1 expression increased anchorage-independent growth in LNCaP and 22Rv1 cells. Cavin-1 co-expression reversed caveolin-1 effects in caveolin-1-positive LNCaP cells. Taken together, these results suggest that caveolin-1 in advanced prostate cancer is present outside of caveolae, because of the lack of cavin-1 expression. Cavin-1 expression attenuates the effects of non-caveolar caveolin-1 microdomains partly via reduced IL-6 microenvironmental function. With circulating caveolin-1 as a potential biomarker for advanced prostate cancer, identification of the molecular pathways affected by cavin-1 could provide novel therapeutic targets.
Collapse
Affiliation(s)
- H Moon
- The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia
| | - C S Lee
- 1] Discipline of Pathology, School of Medicine and Molecular Medicine Research Group, University of Western Sydney, Sydney, New South Wales, Australia [2] Department of Anatomical Pathology, Liverpool Hospital, Sydney, New South Wales, Australia
| | - K L Inder
- The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia
| | - S Sharma
- 1] Discipline of Pathology, School of Medicine and Molecular Medicine Research Group, University of Western Sydney, Sydney, New South Wales, Australia [2] Department of Anatomical Pathology, Liverpool Hospital, Sydney, New South Wales, Australia
| | - E Choi
- 1] The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia [2] School of Veterinary Science, The University of Queensland, Brisbane, Queensland, Australia
| | - D M Black
- The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia
| | - K-A Lê Cao
- Queensland Facility for Advanced Bioinformatics, The University of Queensland, Brisbane, Queensland, Australia
| | - C Winterford
- School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
| | - J I Coward
- Mater Research, Translational Research Institute, Brisbane, Queensland, Australia
| | - M T Ling
- Australian Prostate Cancer Research Centre-Queensland and Institute for Biomedical Health & Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | | | - D J Craik
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
| | - R G Parton
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
| | - P J Russell
- Australian Prostate Cancer Research Centre-Queensland and Institute for Biomedical Health & Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - M M Hill
- The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia
| |
Collapse
|